The AMR Action Fund announces appointment of CEO, Henry B. Skinner, PhD
Today, the AMR Action Fund announced the appointment of its first Chief Executive Officer (CEO), Henry B. Skinner, PhD. The AMR Action Fund (www.AMRactionfund.com) is a ground-breaking partnership that was launched in July 2020 by more than 20 leading pharmaceutical companies. It aims to invest over US$1 billion to strengthen and accelerate clinical research of innovative new antibiotics that are addressing the most resistant bacteria and life-threatening infections, as well as provide technical support to biotech companies developing assets in this field. The AMR Action Fund is the largest collaborative venture ever created to address antimicrobial resistance (AMR).
OUR UNDERWRITERS
Unrestricted financial support kindly provided by
 |
Antimicrobial Resistance Fighter Coalition |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
